Anatara Lifesciences 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

David Brookes

최고 경영자

AU$172.9k

총 보상

CEO 급여 비율	86.7%
CEO 임기	5.8yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	5.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

David Brookes 의 보수는 Anatara Lifesciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$173k	AU$150k	-AU$1m
Mar 31 2024	n/a	n/a	-AU$2m
Dec 31 2023	n/a	n/a	-AU$2m
Sep 30 2023	n/a	n/a	-AU$2m
Jun 30 2023	AU$198k	AU$152k	-AU$2m
Mar 31 2023	n/a	n/a	-AU$2m
Dec 31 2022	n/a	n/a	-AU$2m
Sep 30 2022	n/a	n/a	-AU$2m
Jun 30 2022	AU$150k	AU$108k	-AU$3m
Mar 31 2022	n/a	n/a	-AU$2m
Dec 31 2021	n/a	n/a	-AU$2m
Sep 30 2021	n/a	n/a	-AU$2m
Jun 30 2021	AU$84k	n/a	-AU$2m
Mar 31 2021	n/a	n/a	-AU$2m
Dec 31 2020	n/a	n/a	-AU$3m
Sep 30 2020	n/a	n/a	-AU$3m
Jun 30 2020	AU$80k	n/a	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$3m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$35k	n/a	-AU$3m

보상 대 시장: David 의 총 보상 ($USD 112.65K ) Australian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 297.87K ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

David Brookes (64 yo)

5.8yrs

테뉴어

AU$172,911

보상

Dr. David Lionel Brookes, MBBS, FACRRM, FAICD, served as an Independent Non-Executive Director of Island Pharmaceuticals Limited since October 1, 2020 until September 19, 2024. He serves as Managing Direct...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Brookes	Executive Chairman & MD	no data	AU$172.91k	0.60% A$ 65.5k
John Michailidis	COO & Executive Director	2.4yrs	AU$170.79k	0.62% A$ 68.4k
Simon Erskine	Chief Development Officer	3yrs	AU$289.40k	데이터 없음
Stephen Denaro	Company Secretary	10.8yrs	데이터 없음	데이터 없음
Hayley van der Meer	Commercial Manager	no data	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

경험이 풍부한 관리: ANR 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Brookes	Executive Chairman & MD	5.8yrs	AU$172.91k	0.60% A$ 65.5k
John Michailidis	COO & Executive Director	1.1yrs	AU$170.79k	0.62% A$ 68.4k
Peter Gibson	Chairman of Product Development Advisory Board	5.9yrs	데이터 없음	데이터 없음
Rebecca Burgell	Member of Product Development Advisory Board	5.9yrs	데이터 없음	데이터 없음
Jakob Begun	Member of Product Development Advisory Board	5.9yrs	데이터 없음	데이터 없음
Barry Campbell	Member of Product Development Advisory Board	5.9yrs	데이터 없음	데이터 없음
Simon Keely	Member of Product Development Advisory Board	5.9yrs	데이터 없음	데이터 없음
Nicholas Haslam	Non-Executive Director	1.9yrs	AU$66.60k	데이터 없음

5.9yrs

평균 재임 기간

경험이 풍부한 이사회: ANR 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.

Anatara Lifesciences 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024

No independent directors

No independent directors

No independent directors

Less than half of directors are independent

Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023

Recent updates

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.75 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.

Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.

No independent directors

New major risk - Shareholder dilution

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.315185 million.

New major risk - Shareholder dilution

No independent directors

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

No independent directors

Less than half of directors are independent

Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Anatara Lifesciences Ltd Announces board Changes

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited, Annual General Meeting, Nov 11, 2022

Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial

Insufficient new directors

Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer

Insufficient new directors

Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

Anatara Lifesciences Provides Clinical Trials Update

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited Provides Clinical Trials Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

High number of new directors

Anatara Lifesciences Limited Provides Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome

Anatara Lifesciences Provides This Update on Clinical Trial Activities

Insider recently sold AU$177k worth of stock

First half 2021 earnings released: AU$0.016 loss per share (vs AU$0.036 loss in 1H 2020)

Anatara Lifesciences Receives Ethics Approval to Start IBS Trial

Anatara Lifesciences Announces Successful Poultry Trial

New 90-day high: AU$0.22

Anatara Lifesciences Limited Announces Cessation of Tracie Elizabeth Ramsdale as Director

Anatara Lifesciences Limited Announces Retirement of Tracie Ramsdale as Non-Executive Director

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간